In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Baxter, Sangamo develop vascular disease therapeutics

Executive Summary

Sangamo BioSciences (transcription factors) has licensed Baxter International's cardiovascular group (therapeutics for cardiovascular and other diseases; soon to be spun off as an independent company called Edwards Lifesciences) exclusive worldwide rights to develop and commercialize its zinc finger DNA binding proteins (ZFPs) for use in cardiovascular and other vascular diseases.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register